874899-73-7

Basic information

• Product Name: Phosphonium, [[2-(acetylamino)-4-thiazolyl]methyl]triphenyl-, chloride
• CAS NO: 874899-73-7
• Molecular Formula: C24H22N2OPS.Cl
• Molecular Weight: 452.944
• Mol File: 874899-73-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Phosphonium, [[2-(acetylamino)-4-thiazolyl]methyl]triphenyl-, chloride(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonium, [[2-(acetylamino)-4-thiazolyl]methyl]triphenyl-, chloride(874899-73-7)
• EPA Substance Registry System: Phosphonium, [[2-(acetylamino)-4-thiazolyl]methyl]triphenyl-, chloride(874899-73-7)

Safety Data

• Hazardous Substances Data: 874899-73-7(Hazardous Substances Data)

Upstream product

• 7460-59-5 N-(4-(chloromethyl)thiazol-2-yl)acetamide 
• 603-35-0 triphenylphosphine 

Downstream Products

• 1442469-23-9 tert-butyl (4-{4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenethyl}-1H-imidazol-2-yl)carbamate 
• 874901-16-3 3-{4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl}propanoic acid 
• 874899-75-9 methyl 3-{4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl}propanoate 
• 874899-74-8 methyl (2E)-3-{4-[(E)-2-(2-acetamido-1,3-thiazol-4-yl)vinyl]phenyl}acrylate 
• 776295-05-7 N-(4-{2-[4-(2-aminoethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide 
• 874901-22-1 N-[4-(2-{4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide 
• 874901-20-9 N-[4-((E)-2-{4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}vinyl)-1,3-thiazol-2-yl]acetamide 
• 1174632-84-8 N-{4-[2-(3-hydroxyphenyl)vinyl]-1,3-thiazol-2-yl}acetamide 

Relevant articles and documents

Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema

Vascular adhesion protein-1 (VAP-1), an amine oxidase that is also known as a semicarbazide-sensitive amine oxidase (SSAO), is present in particularly high levels in human plasma, and is considered a potential therapeutic target for various inflammatory diseases, including diabetes complications such as macular edema. In our VAP-1 inhibitor program, structural modifications following high-throughput screening (HTS) of our compound library resulted in the discovery that thiazole derivative 10, which includes a guanidine group, shows potent human VAP-1 inhibitory activity (IC50 of 230 nM; rat IC 50 of 14 nM). Moreover, compound 10 exhibited significant inhibitory effects on ocular permeability in STZ-induced diabetic rats.

THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY

A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is -CONH- or -NR1CO- wherein R1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: or wherein R2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, -NH- or ; D is a bond, -CS- or -CO-; E is a bond or -NH-; F is a bond, -CO-, -O- or -SO2-; and G is lower alkyl, optionally protected amino, -OH, phenyl, or ; and R3 is lower alkyl, provided that when Z is a group of the formula: , then G should not be amino, when Z is a group of the formula: , then G should not be , when Z is a group of the formula: and G is optionally protected amino, then D should be -CS-, or then A should be lower alkylene, B or E should be -NH- and F should be -CO-; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.